Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to the captioned subject, please find enclosed herewith the Earnings call Transcript of the Company''s Q2FY24 Earnings Conference Call held on November 9, 2023. Neogen Chemicals Ltd - 542665 - Recording Of Investors/ Earnings Call Conference Call Held On 09-11-2023
Recording of Investors/ earnings Call Conference call held on 09-11-2023. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording of Investor/ Earnings Conference call held on 09-11-2023 at 5 pm Neogen Chemicals Ltd - 542665 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Mutual Fund Q2FY24 Quarterly Result Announced for Neogen Chemicals Ltd.
Neogen Chemicals announced Q2FY24 results: In Q2FY24, revenue was Rs 161.7 crore, with a growth of 9% YoY. This was achieved despite the challenging external environment aggravated by global inventory destocking, the slowdown in key export markets, and geopolitical uncertainties among others. Recent capacity expansions, stable demand, and contributions from BuLi Chem supported the growth momentum. EBITDA at Rs 25.9 crore was higher by 7% YoY. Growth in profitability was reflected by an improved product mix and a reduction in key input and RM costs. Profit after tax (PAT) stood at Rs 7.9 crore, lower by 20% YoY compared to Rs 9.9 crore in Q2FY23. PAT was lower due to higher finance costs and depreciation related to ongoing CAPEX initiatives undertaken by the Company. Strategic debt repayment from recent preference share proceeds will help lower the finance expenses in the near term. Earnings per share (EPS) for Q2FY24 stood at Rs 3.17 per share (Rs. 3.95 per share in Q2FY23). Commenting on the Q2FY24 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said, “I am pleased to share that we have maintained a consistent performance despite persistent external headwinds that have adversely impacted the end-user demand. We achieved a 9% growth in revenues along with a 7% improvement in EBITDA on a YoY basis. Positive contributions from recently acquired BuLi Chem, rationalisation of key RM & input costs, along with efficient inventory management were notable drivers of performance during the quarter. In a significant development, we recently raised ~Rs 253 crore through preferential allotment to leading institutional investors. I would like to express my appreciation for the trust placed in us and the support extended toward our future growth endeavors. We will carefully deploy these funds to establish a strong presence in the Battery Materials space while sustaining the growth momentum in the existing business. We are rapidly progressing along the outlined growth path. BuLi Chem has started contributing and also achieved break-even. This will further ramp up as we move along. The contribution from value-added products is also increasing, and our endeavor is to add more complex products by leveraging our R&D; expertise and manufacturing capabilities. Our efforts related to Battery Materials are advancing successfully. Our project using MUIS technology is evolving positively, and we are on schedule to finalize the design work by the end of this year. Our interactions with key customers for both Lithium Electrolyte Salts and Electrolytes are making good progress, and we are seeing strong interest from international customers, especially for Electrolyte Salts. We are confident of garnering a significant share as the transition to EVs gains momentum. Overall, we are well poised to capitalize on the upcoming opportunities. Building upon the solid foundation, we remain steadfast in our pursuit to not only elevate our performance momentum but also consistently enhance value for our stakeholders.” Result PDF Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, please find enclosed herewith the press release on the unaudited financial results (standalone and consolidated) of the company for the quarter and half year ended September 30, 2023. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Investor Presentation
Earnings Presentation on unaudited financial results of the company for the Half year ended September 30, 2023 Neogen Chemicals Ltd - 542665 - Outcome Of Board Meeting Held On Wednesday, November 8, 2023.
The Board has in its meeting held today approved the following: 1) Unaudited results for the quarter and half year ended September 30, 2023 2) Subscription of upto 40 lakhs equity shares of Neogen Ionics Limited the wholly owned subsidiary (WOS) at a price of Rs. 10 each 3)Investing by way of Loan upto Rs. 250 crores in its WOS Neogen Ionics Limited. Neogen Chemicals Ltd - 542665 - Outcome Of Board Meeting Held On Wednesday, November 8, 2023.
Approval of Financial Results for the Quarter and Half year ended September 30, 2023 by the Board of Directors in its meeting held on November 8 , 2023 Neogen Chemicals Ltd - 542665 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 8, 2023
The Board of Directors of the Company had at its meeting held today i.e., Wednesday, November 8, 2023, inter alia considered and approved the following: 1. Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended September 30, 2023 2. Subscription of upto 40,00,000 equity shares at a price of Rs. 10 each on rights issue basis of its Wholly Owned Subsidiary i.e., Neogen Ionics Limited. 3.3. Investing by way of Loan up to Rs. 250 Crores in its Wholly Owned Subsidiary (WOS) i.e., Neogen Ionics Limited